Literature DB >> 16333444

New modalities in oncology: ribozymes.

C Casey Cunningham1.   

Abstract

Year:  2002        PMID： 16333444      PMCID： PMC1276617          DOI： 10.1080/08998280.2002.11927847

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  11 in total

Review 1.  Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy.

Authors:  J A Zaia; S Chatterjee; K K Wong; D Elkins; N R Taylor; J J Rossi
Journal:  Ann N Y Acad Sci       Date:  1992-10-28       Impact factor: 5.691

2.  Cellular uptake properties of a 2'-amino/2'-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA.

Authors:  P L Fell; A J Hudson; M A Reynolds; N Usman; S Akhtar
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1997-08

Review 3.  The structure, function and application of the hammerhead ribozyme.

Authors:  K R Birikh; P A Heaton; F Eckstein
Journal:  Eur J Biochem       Date:  1997-04-01

Review 4.  Ribozymes: from mechanistic studies to applications in vivo.

Authors:  J Ohkawa; T Koguma; T Kohda; K Taira
Journal:  J Biochem       Date:  1995-08       Impact factor: 3.387

5.  Three-dimensional structure of a hammerhead ribozyme.

Authors:  H W Pley; K M Flaherty; D B McKay
Journal:  Nature       Date:  1994-11-03       Impact factor: 49.962

6.  Vascular permeability factor, an endothelial cell mitogen related to PDGF.

Authors:  P J Keck; S D Hauser; G Krivi; K Sanzo; T Warren; J Feder; D T Connolly
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

7.  Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.

Authors:  P A Pavco; K S Bouhana; A M Gallegos; A Agrawal; K S Blanchard; S L Grimm; K L Jensen; L E Andrews; F E Wincott; P A Pitot; R J Tressler; C Cushman; M A Reynolds; T J Parry
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

8.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

9.  The intervening sequence RNA of Tetrahymena is an enzyme.

Authors:  A J Zaug; T R Cech
Journal:  Science       Date:  1986-01-31       Impact factor: 47.728

10.  Oligonucleotide facilitators may inhibit or activate a hammerhead ribozyme.

Authors:  E Jankowsky; B Schwenzer
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.